Table 1 Baseline demographics of 204 patients stratified by liraglutide treatment
All patients (n = 204) | Lira+ (n = 55) | Lira- (n = 149) | P value | |
|---|---|---|---|---|
Age (years) | 61 ± 10 | 61 ± 9 | 61 ± 10 | 0.844 |
Male, n (%) | 149 (73) | 38 (69) | 111 (74) | 0.440 |
Body mass index (kg/m2) | 30.5 ± 4.6 | 32.1 ± 4.8 | 29.9 ± 4.8 | 0.002 |
Hypertension, n (%) | 139 (68) | 41 (75) | 98 (66) | 0.214 |
Dyslipidemia, n (%) | 161 (79) | 43 (78) | 118 (79) | 0.875 |
Active smokers, n (%) | 47 (23) | 10 (18) | 37 (25) | 0.317 |
Pack years (years/20 cigarettes daily) | 15.9 ± 19.1 | 14.5 ± 16.7 | 16.4 ± 20.0 | 0.519 |
Duration of diabetes (years) | 10.8 ± 7.0 | 13.5 ± 7.0 | 9.7 ± 8.9 | 0.003 |
Medication at baseline | ||||
- Insulin | 80 (39) | 28 (51) | 52 (35) | 0.038 |
- Biguanide | 169 (82) | 51 (98) | 118 (80) | 0.023 |
- DPP-4 inhibitor | 29 (14) | 1 (1) | 28 (19) | 0.002 |
- Sulfonylureas | 36 (18) | 13 (24) | 23 (15) | 0.173 |
- SGLT2 inhibitor | 18 (9) | 5 (9) | 13 (9) | 0.935 |
- Acetylsalicylic acid | 24 (12) | 5 (9) | 19 (13) | 0.471 |
- Beta-blocker | 18 (9) | 6 (11) | 12 (8) | 0.523 |
- ACE inhibitor/ ARB | 131 (64) | 38 (69) | 93 (63) | 0.779 |
- Lipid-lowering, n (%) | 154 (75) | 44 (80) | 110 (74) | 0.363 |
- Duration of lipid-lowering (years) | 6.5 ± 5.8 | 8.1 ± 5.6 | 5.8 ± 5.8 | 0.009 |
Laboratory findings | ||||
- LDL (mmol/L) | 2.0 ± 0.8 | 1.9 ± 0.8 | 2.0 ± 0.8 | 0.482 |
- HDL (mmol/L) | 1.2 ± 0.3 | 1.2 ± 0.3 | 1.2 ± 0.4 | 0.434 |
- Triglycerides (mmol/L) | 2.0 ± 1.0 | 2.3 ± 1.2 | 1.9 ± 0.9 | 0.022 |
- HbA1c (mmol/mol) | 60.2 ± 14.2 | 65.0 ± 15.7 | 58.4 ± 13.2 | 0.003 |
- hsCRP (mg/L) | 2.8 ± 3.5 | 2.9 ± 3.6 | 2.7 ± 3.5 | 0.726 |
CAC score (Agatston units) | 416 IQR (0-481) | 509.1 IQR (0-481) | 381 IQR (1-460) | 0.297 |